Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

Trial Details

NCT ID
NCT06793956
Phase
PHASE1
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Sintilimab and Linperlisib Combination Treatment
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Pathologically confirmed extranodal NKTCL.
  • Voluntary participation in the clinical study; fully understand the study, and have signed the written informed consent form.
  • Age ≥ 18 years.
  • Relapsed or refractory NKTCL after failure of at least one line of asparaginase-based chemotherapy or chemoradiotherapy regimen.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →